New Findings from Fudan University Describe Advances in Beta-Lactam Antibiotics (Budget impact analysis of aztreonam-avibactam for metallo-b-lactamase carbapenem-resistant enterobacterales infections in China): Drugs and Therapies – Beta-Lactam Antibiotics

2026 MAY 14 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Drugs and Therapies - Beta-Lactam Antibiotics have been published. According to news reporting from Shanghai, People’s Republic of China, by NewsRx journalists, research stated, “To evaluate the budget impact on the China’s basic medical insurance fund (BMIF) following the inclusion of aztreonam-avibactam (ATM-AVI) for metallo-b-lactamase carbapenem-resistant Enterobacterales (MBL-CRE) infections in the National Reimbursement Drug List (NRDL). A budget impact model was developed with a 2-year time horizon (2026-2027) from the perspective of China’s basic medical insurance.”

The news correspondents obtained a quote from the research from Fudan University, “The analysis included drug acquisition costs and other direct medical costs. Relevant data were collected from published literature, and supplemented through expert consultation. The study compared costs under two scenarios with and without ATM-AVI reimbursement to estimate its impact on BMIF. One way sensitivity analyses were conducted to identify key parameters influencing the results. After the inclusion of ATM-AVI in the NRDL, the BMIF was projected to save 152,156,598 Chinese yuan (21,310,448 United States dollar) and 210,914,875 Chinese yuan (29,539,898 United States dollar) in 2026 and 2027, respectively. Following reimbursement, ATM-AVI was expected to yield 291 and 342 additional cured patients, 804 and 888 fewer deaths, 11,256 and 13,031 fewer intensive care unit days, and 11,336 and 13,071 fewer total hospitalization days in 2026 and 2027, respectively. Across all parameter variations, ATM-AVI remained cost-saving to BMIF.”

According to the news reporters, the research concluded: “In China, timely reimbursement of innovative antibiotics can simultaneously improve patient outcomes and reduce medical insurance fund expenditure, underscoring the value of value-based reimbursement policies in promoting access to effective therapies while supporting the sustainability of the health insurance system.”

This research has been peer-reviewed.

For more information on this research see: Budget impact analysis of aztreonam-avibactam for metallo-b-lactamase carbapenem-resistant enterobacterales infections in China. Infection, 2026. Infection can be contacted at: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany. (Springer - www.springer.com; Infection - http://www.springerlink.com/content/0300-8126/)

Our news journalists report that additional information may be obtained by contacting Kemiao Zhang, School of Public Health, Fudan University, 130 Dongan Rd, Xuhui, 200032, Shanghai, People’s Republic of China. Additional authors for this research include Junling Weng, Qiang Liu, Dunming Xiao, Zichun Zhou, Yi Yang, Xin Li and Yingyao Chen.

Publisher contact information for the journal Infection is: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany.

(Our reports deliver fact-based news of research and discoveries from around the world.)